HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

November 2022

Treating NMOSD Early in the Disease Course: Inebilizumab’s Efficacy in N-MOmentum

November 26, 2022

Clinical Viewpoint

Bruce Cree, MD, PhD, MAS, FAAN, offered his perspective on data from the phase 2/3 N-MOmentum trial of the recently approved inebilizumab (Uplizna; Horizon Therapeutics) and why the therapy stands out from other NMOSD treatments.

The Relationship Between Epstein-Barr Virus and Multiple Sclerosis

November 23, 2022


The paradigm-shifting evidence of the link between MS and EBV does not exist in isolation. In fact, the relationship has been suspected for more than 40 years, and evidence therein has been accumulating over the past 2 decades.

Revealing the Unseen in Multiple Sclerosis

November 21, 2022

Letter From the Editor

Cognitive and other symptoms in multiple sclerosis can be invisible—meaning not readily observed in the individual. However, their impact on a patient’s life can be obvious.

Longer Periods Between Natalizumab Dosing Might Result in Increased T2 Lesion Count

October 11, 2022

In the Headlines

New data from the NOVA trial showed differences in the number of T2 lesions in patients with relapsing-remitting multiple sclerosis at 72 weeks of treatment with natalizumab (Tysabri; Biogen), though seemingly driven by data from only 2 participants with extreme new or newly enlarging T2 hyperintense lesion numbers.

Ofatumumab Outperforms Teriflunomide in Newly Diagnosed, Treatment-Naïve Multiple Sclerosis

September 28, 2022

In the Headlines

Consistent with the overall population, newly diagnosed, treatment-naïve patients with MS showed better relapse rates, all-cause disability worsening—including progression independent of relapse activity—with ofatumumab over teriflunomide.

MS Treatment Glatiramer Acetate Depot Injection Proves Positive in Topline Phase 3 Data

September 21, 2022

In the Headlines

The Mapi Pharma treatment, administered intramuscularly at 40 mg, reduced annualized relapse rates among a population of patients with relapsing multiple sclerosis. Secondary outcomes are still being analyzed.